- Home
- RBCAA vs JANX Comparison
RBCAA vs JANX Comparison
Compare RBCAA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBCAA
- JANX
- Stock Information
- Founded
- RBCAA 1974
- JANX 2017
- Country
- RBCAA United States
- JANX United States
- Employees
- RBCAA N/A
- JANX N/A
- Industry
- RBCAA Major Banks
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- RBCAA Finance
- JANX Health Care
- Exchange
- RBCAA Nasdaq
- JANX Nasdaq
- Market Cap
- RBCAA 1.3B
- JANX 1.4B
- IPO Year
- RBCAA 1998
- JANX 2021
- Fundamental
- Price
- RBCAA $65.61
- JANX $27.02
- Analyst Decision
- RBCAA Hold
- JANX Strong Buy
- Analyst Count
- RBCAA 1
- JANX 11
- Target Price
- RBCAA N/A
- JANX $76.55
- AVG Volume (30 Days)
- RBCAA 22.5K
- JANX 1.2M
- Earning Date
- RBCAA 10-17-2025
- JANX 11-06-2025
- Dividend Yield
- RBCAA 2.76%
- JANX N/A
- EPS Growth
- RBCAA 24.34
- JANX N/A
- EPS
- RBCAA 6.44
- JANX N/A
- Revenue
- RBCAA $378,269,000.00
- JANX $439,000.00
- Revenue This Year
- RBCAA $15.62
- JANX N/A
- Revenue Next Year
- RBCAA N/A
- JANX $89.91
- P/E Ratio
- RBCAA $10.17
- JANX N/A
- Revenue Growth
- RBCAA 16.59
- JANX N/A
- 52 Week Low
- RBCAA $56.79
- JANX $21.73
- 52 Week High
- RBCAA $80.68
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- RBCAA 34.22
- JANX 52.81
- Support Level
- RBCAA $64.52
- JANX $27.40
- Resistance Level
- RBCAA $72.47
- JANX $29.21
- Average True Range (ATR)
- RBCAA 1.73
- JANX 1.83
- MACD
- RBCAA -0.33
- JANX 0.01
- Stochastic Oscillator
- RBCAA 13.72
- JANX 37.35
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.